Loading stock data…
NVCT
$8.54-0.02 (-0.23%)
Market ClosedLast close May 1
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvectis Pharma, Inc. in the Healthcare sector is trading at $8.54. The stock is currently 23% below its 52-week high of $11.15, remaining 15.6% above its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why NVCT maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.54
Potential Upside
5%
Whystock Fair Value$8.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$233.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-119.84%
Volume
Today's trading volume
35,569
Recent News
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders
Key Insights The considerable ownership by retail investors in Nuvectis Pharma indicates that they collectively have a...
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Nuvectis Pharma, Inc. ( NASDAQ:NVCT...
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure
Nuvectis will concentrate efforts on progressing its cancer drug NXP900 after the failure of NXP800.